News

Topline results from this study are now expected in Q1 2016. GPR84 was identified as a target for these diseases through Galapagos’ target discovery platform and GLPG1205 is

These funds will be used to initiate a proof-of-concept study of the CRTH2 antagonist OC459 in severe eosinophilic asthma, and to accelerate the development of both OC459 and

CAT-1004 is an oral small-molecule that the Company believes has the potential to be a disease-modifying therapy for DMD patients, regardless of the underlying dystrophin mutation, by inhibiting

Altius (higher in Latin) will be pioneering new technologies and approaches for decoding how genes are controlled and how a cell’s "operating system" functions in health and disease.

LBI is an internationally renowned organization dedicated to research in the fields of tissue engineering, stem cells, and regenerative medicine. "Collaborating with the Ludwig Boltzmann Institute gives Hemostemix

AKP-11 is a novel First-in-Class topical Sphingosine 1-Phosphate receptor-1 (S1P1) modulator for the treatment of mild-to-moderate plaque psoriasis in patients. Patients will be treated daily for six weeks

The company said that Zomig is the first nasal-delivered prescription medicine approved to treat acute migraine attacks in pediatric patients. The approval came after the FDA’s review of

Rapivab is an intravenous (IV) treatment indicated in the US for acute uncomplicated influenza in adults aged 18 years and older. bioCSL general manager and senior vice-president Dr

As part of the deal, the two firms will carry out collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Sumitomo’s choice, with a